Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo-controlled study

What Was Tested

Researchers studied Amylin (Islet Amyloid Polypeptide) in this randomized controlled trial publication.

Hyperinsulinemia in association with GH excess is considered a compensatory response to insulin resistance, but the possibility of alternative insulinotropic mechanisms has not been investigated in vivo.

It is also unknown how GH influences the secretion from pancreatic beta-cells of amylin, a peptide which regulates prandial glucose homeostasis and may be linked to development of beta-cell dysfunction.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

All participants underwent an oral glucose tolerance test (OGTT) at 0 and 4 months.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.

As a double-blind Amylin (Islet Amyloid Polypeptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Amylin (Islet Amyloid Polypeptide) could be set against what happens without it.

The Amylin (Islet Amyloid Polypeptide) group and the comparison group ran side by side rather than switching.

What Was Measured

PubMed files the paper under topics including Amyloid, Fasting, Gastric Inhibitory Polypeptide, Gastrointestinal Hormones, Glucagon, Glucagon-Like Peptide 1 and Glucagon-Like Peptides.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Amylin (Islet Amyloid Polypeptide).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2000 (European journal of endocrinology), a journal based in England.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.